A PET study of tiagabine treatment implicates ventral medial prefrontal cortex in generalized social anxiety disorder.

Department of Psychiatry, Psychiatric Neuroscience Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA.
Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology (Impact Factor: 7.83). 07/2008; 34(2):390-8. DOI: 10.1038/npp.2008.69
Source: PubMed

ABSTRACT Corticolimbic circuitry has been implicated in generalized social anxiety disorder (gSAD) by several neuroimaging symptom provocation studies. However, there are limited data regarding resting state or treatment effects on regional cerebral metabolic rate of glucose uptake (rCMRglu). Given evidence for anxiolytic effects conferred by tiagabine, a gamma-aminobutyric acid (GABA) reuptake inhibitor, the present [(18)F] fluorodeoxyglucose-positron emission tomography ((18)FDG-PET) study sought to (1) compare resting rCMRglu between healthy control (HC) and pretreatment gSAD cohorts, (2) examine pre- to post-tiagabine treatment rCMRglu changes in gSAD, and (3) determine rCMRglu predictors of tiagabine treatment response. Fifteen unmedicated individuals with gSAD and ten HCs underwent a baseline (pretreatment) resting-state (18)FDG-PET scan. Twelve of the gSAD individuals completed an open, 6-week, flexible dose trial of tiagabine, and underwent a second (posttreatment) resting-state (18)FDG-PET scan. Compared to the HC subjects, individuals with gSAD demonstrated less pretreatment rCMRglu within the anterior cingulate cortex and ventral medial prefrontal cortex (vmPFC) at baseline. Following tiagabine treatment, vmPFC rCMRglu increased significantly in the gSAD group. Further, the magnitude of treatment response was inversely correlated with pretreatment rCMRglu within vmPFC. Taken together the present findings converge with neuroimaging findings from studies of social cognition in healthy individuals and symptom provocation in gSAD to support a role for the vmPFC in the pathophysiology of gSAD. Given the pharmacological profile of tiagabine, these findings suggest that its therapeutic effects in gSAD may be mediated by GABAergic modulation within the vmPFC.


Available from: Darin D Dougherty, Mar 24, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Social anxiety disorder (SAD) is one of the most frequent anxiety disorders. The landmark meta-analysis of functional neuroimaging studies by Etkin & Wager (2007) revealed primarily the typical fear circuit as overactive in SAD. Since then, new methodological developments such as functional connectivity and more standardized structural analyses of grey and white matter have been developed. We provide a comprehensive update and a meta-analysis of neuroimaging studies in SAD since 2007 and present a new model of the neurobiology of SAD. We confirmed the hyperactivation of the fear circuit (amygdala, insula, anterior cingulate and prefrontal cortex) in SAD. In addition, task-related functional studies revealed hyperactivation of medial parietal and occipital regions (posterior cingulate, precuneus, cuneus) in SAD and a reduced connectivity between parietal and limbic and executive network regions. Based on the result of this meta-analysis and review, we present an updated model of SAD adopting a network-based perspective. The disconnection of the medial parietal hub in SAD extends current frameworks for future research in anxiety disorders.
    Neuroscience & Biobehavioral Reviews 11/2014; 47:260-280. DOI:10.1016/j.neubiorev.2014.08.003 · 10.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: form only given, as follows. The group method of data handling (GMDH), a data analysis technique for identification of nonlinear complex systems, is a feature-based mapping neural network. It is also an example of a polynomial neural network (PNN). The PNN can be successfully trained to interpolate an unknown function by observing a few samples. The PNN is used to interpolate robot forward and inverse kinematics computations (FKC and IKC). The FKC and IKC are, respectively, designed to find the mapping from the joint space to the Cartesian space, and the mapping from the Cartesian space to the joint space. A PNN simulation software package has been developed for solving both the FKC and the IKC. The simulation was performed in a two-degree-of-freedom manipulator. The solutions of the built FKC and IKC networks were compared with the analytic equations. The PNN successfully learns the indicated path
    Neural Networks, 1991., IJCNN-91-Seattle International Joint Conference on; 01/1991
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Generalized social anxiety disorder (GSAD) is characterized by aberrant patterns of amygdala-frontal connectivity to social signals of threat and at rest. The neuropeptide oxytocin (OXT) modulates anxiety, stress and social behaviors. Recent functional neuroimaging studies suggest these effects are mediated through OXT's effects on amygdala reactivity and/or amygdala-frontal connectivity. The aim of the current study was to examine OXT's effects on amygdala-frontal resting-state functional connectivity (rsFC) in GSAD patients and healthy controls (HC). In a randomized, double-blind, cross-over design, 18 GSAD and 18 HC participants received intranasal OXT (24 IU or 40.32 μg) or placebo prior to resting-state functional magnetic resonance imaging. In individuals with GSAD, OXT enhanced rsFC of the left and right amygdala with rostral ACC/mPFC, and in doing so, reversed (i.e., 'normalized') the reduced amygdala-frontal connectivity observed relative to HCs evident on placebo. Higher social anxiety severity in GSAD subjects correlated with lower amygdala-ACC/mPFC connectivity on placebo and higher social anxiety also correlated with greater enhancement in amygdala-frontal connectivity induced by OXT. These findings show that OXT modulates a neural circuit known for social threat processing and emotion regulation, suggesting a neural mechanism by which OXT may play a role in the pathophysiology and treatment of social anxiety disorder.Neuropsychopharmacology accepted article preview online, 5 March 2014; doi:10.1038/npp.2014.53.
    Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 03/2014; DOI:10.1038/npp.2014.53 · 7.83 Impact Factor